EMA — authorised 27 August 1997
- Application: EMEA/H/C/000139
- Marketing authorisation holder: Pfizer Europe MA EEIG
- Local brand name: BeneFIX
- Indication: Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor-IX deficiency).
- Status: approved